Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Jul 27, 2023

SELL
$34.73 - $43.33 $13,509 - $16,855
-389 Reduced 6.48%
5,615 $230,000
Q1 2023

May 17, 2023

SELL
$33.58 - $41.2 $91,740 - $112,558
-2,732 Reduced 31.27%
6,004 $214,000
Q4 2022

Feb 21, 2023

BUY
$37.12 - $46.52 $52,116 - $65,314
1,404 Added 19.15%
8,736 $329,000
Q3 2022

Nov 14, 2022

SELL
$36.54 - $48.66 $39,097 - $52,066
-1,070 Reduced 12.74%
7,332 $325,000
Q2 2022

Aug 12, 2022

SELL
$31.71 - $43.0 $22,070 - $29,928
-696 Reduced 7.65%
8,402 $312,000
Q1 2022

May 02, 2022

BUY
$29.88 - $37.04 $71,024 - $88,044
2,377 Added 35.37%
9,098 $337,000
Q4 2021

Jan 28, 2022

SELL
$25.61 - $35.1 $110,046 - $150,824
-4,297 Reduced 39.0%
6,721 $205,000
Q3 2021

Nov 16, 2021

SELL
$33.54 - $40.55 $6,305 - $7,623
-188 Reduced 1.68%
11,018 $379,000
Q2 2021

Aug 10, 2021

SELL
$34.54 - $47.25 $61,895 - $84,672
-1,792 Reduced 13.79%
11,206 $454,000
Q1 2021

May 13, 2021

SELL
$42.51 - $63.78 $323,203 - $484,919
-7,603 Reduced 36.91%
12,998 $616,000
Q4 2020

Feb 04, 2021

BUY
$45.3 - $60.27 $42,989 - $57,196
949 Added 4.83%
20,601 $1.17 Million
Q3 2020

Nov 09, 2020

BUY
$47.45 - $62.95 $86,975 - $115,387
1,833 Added 10.29%
19,652 $963,000
Q2 2020

Jul 31, 2020

SELL
$46.85 - $61.05 $18,693 - $24,358
-399 Reduced 2.19%
17,819 $1.05 Million
Q1 2020

May 06, 2020

BUY
$41.6 - $63.4 $440,752 - $671,723
10,595 Added 138.99%
18,218 $861,000
Q4 2019

Feb 10, 2020

BUY
$53.85 - $65.27 $83,090 - $100,711
1,543 Added 25.38%
7,623 $461,000
Q3 2019

Nov 12, 2019

BUY
$59.06 - $72.15 $73,057 - $89,249
1,237 Added 25.54%
6,080 $365,000
Q2 2019

Aug 05, 2019

BUY
$62.09 - $86.14 $300,701 - $417,176
4,843 New
4,843 $312,000

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $5.15B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track This Portfolio

Track National Asset Management, Inc. Portfolio

Follow National Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of National Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on National Asset Management, Inc. with notifications on news.